Saturday, 31 October 2026European Markets

FINATIS Stock Bearish By 27% In The Last 21 Sessions

Loading stream...

finatis sa (cac 40: fnts.pa), a food distribution company with interests in sports equipment and real estate, witnessed their stock significantly decline by 27.36% over 21 sessions from eur4.02 to eur2.92, with five consecutive losses taking place as the cac 40 fell 1% overall to eur7,331.73.

company overview

finatis was established in paris, france in 1971 and currently operates several prominent supermarket chains like monoprix and casino supermarkets across france and latin america. additionally, this french-based firm maintains an expansive sports equipment market presence through the go sport brand as well as real estate assets with private equity investments.

evaluation of financial health

however, to further evaluate finatis' financial health, its twelve-month earnings per share (eps) stood at eur-24.26 - which represents its profitability - an indication of serious financial turbulence at finatis. for potential investors considering any equity investments with finatis amidst volatile finances and declining stock prices, these economic metrics indicate the need for extensive due diligence and risk assessment before considering making any decisions regarding equity purchases in this company. in an environment characterized by financial turmoil and decreasing stock prices, any decisions must be carefully planned out to minimize losses and ensure success.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com